Sustainability | August 12, 2025
Centrient Pharmaceuticals joins UNGC
Reinforcing commitment to ethical and sustainable growth
Reinforcing commitment to ethical and sustainable growth
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
The company has projected Rs. 5,630 crores of investment and to provide employment to 6,350 people in three phases over a period of eight years
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Subscribe To Our Newsletter & Stay Updated
